Corgenix’s Ebola Test Displays Efficacy in Study
Corgenix Medical’s ReEbov Ebola rapid diagnostic test demonstrated high accuracy in an independent study published in Lancet, a UK medical journal, the Broomfield, Colo., devicemaker said last week.
The study, conducted in Sierra Leone by the non-governmental organization Partners in Health, showed that the point-of-care test had a 100 percent sensitivity rate and a 92 specificity rate, the company says.
In February, the World Health Organization listed the ReEbov test as eligible for procurement and the FDA designated it for emergency use.
As of last month, the WHO reported more than 27,000 confirmed, probable and suspected Ebola cases and more than 11,000 deaths in West Africa, making it the worst outbreak ever recorded, Corgenix claims. — Jason Scott